Home / 2021 / March / 02

Daily Archives: March 2, 2021

ISW Holdings Triples Active Cryptocurrency Mining Fleet with Additional POD5IVE Datacenters

LAS VEGAS, March 02, 2021 (GLOBE NEWSWIRE) — via InvestorWire — ISW Holdings, Inc. (OTC: ISWH) (“ISW Holdings” or the “Company”), a diversified portfolio comprised of essential business lines that serve consumer product demands in decentralized markets, is pleased to announce that, following the signing of hosting agreements with Bit5ive LLC, based in Miami, Florida, and Scrubgrass Generating Company, LLP, based in Kennerdell, Pennsylvania, the Company has successfully tripled its active cryptocurrency mining fleet with the addition of two (2) new POD5IVE datacenters.

The Company now operates a total of three POD5IVE datacenter units and anticipates record acceleration in cash flows, revenue growth and profitability.

The POD5IVE datacenter, produced in partnership with Bit5ive, is based on an evolutionary design. Specifications include:

  • Active Mining Power: 62-92 Th/s depending on the miners.
  • SHA 256 Hashrate: Currently 6,557.28 TH/s.
  • Per POD5IVE quantity: 3x 280-360.
  • Depending on each miner, 1x 280 and type of miner: 3x Up S17/T17, 1x up to S19/T19.
  • Power capacity: Each POD5IVE can go 2x 800A, 2x 1000A or 2x 1200A.
  • Total power capacity per POD5IVE: 4x 920,038.40 Watts (current site is using 800A fuse per service).
  • Container Size: 40′ x 8′.
  • Shelving: 3x with 10 medium Racks, 1x with 4 large racks.
  • Voltage: 415V 3 Phase.
  • Ventilation: Passive airflow with a temperature-controlled evaporative cooler (133,000 CFM total each).
  • Digital smart breakers, virtual power monitoring, auto rebooting and wattage protection.
  • Door lock system (automated, warm air recirculation): Basic locks with keys.
  • Purchase price per POD: $168,000.
  • Manufacturing & delivery: 10-12 weeks.
  • Master Capacity: 280 for S19/T19.

Alonzo Pierce, president and chairman of ISW Holdings, commented, “We have now tripled our mining activity with the addition of two new POD5IVE mining pods. The Company will continue to significantly add to our fleet over the coming quarters. We are also building a valuable track record with our mining pods, which will validate the strong value presented when we enter our next phase and begin marketing the Proceso POD5IVE Datacenter as a self-contained, high-efficiency, low-maintenance cryptocurrency mining equipment solution.”

About ISW Holdings
ISW Holdings, Inc., through its in-house operations and strategic partnerships, has invested in growing operations targeting the home healthcare, telehealth, cryptocurrency mining and supply chain management industries. The Company’s expertise lies in strategic brand development, early growth facilitation, as well as brand identity through a proprietary procurement process. Management maneuvers its proprietary companies through critical stages of market development, which include conceptualization, go-to-market strategies, engineering, product integration and distribution efficiency.

For more information, visit www.iswholdings.com.

Forward-Looking Statements
This press release may contain forward-looking statements that involve risks and uncertainties. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology including “could,” “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential” and the negative of these terms or other comparable terminology. While these forward-looking statements, and any assumptions upon which they are based, are made in good faith and reflect our current judgment regarding the direction of our business, actual results will almost always vary, sometimes materially, from any estimates, predictions, projections, assumptions or other future performance suggested in this report. Except as required by applicable law, we do not intend to update any of the forward-looking statements so as to conform these statements to actual results. Investors should refer to the risks disclosed in the Company’s reports filed from time to time with OTC Markets (www.otcmarkets.com).

Wire Service Contact

InvestorWire (IW)
Los Angeles, California
www.InvestorWire.com
212.418.1217 Office
Editor@InvestorWire.com

Philips partners with DiA Imaging Analysis to enhance ultrasound with AI-based image quantification

March 2, 2021

Amsterdam, the Netherlands and Be’er Sheva, Israel – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and DiA Imaging Analysis Ltd., a leading provider of AI-powered applications for ultrasound, today announced a strategic partnership* to deliver automated solutions to clinicians at the point-of-care. Philips’ industry leading ultrasound image quality combined with DiA’s AI library of automated solutions will help increase diagnostic confidence, operational efficiency, and access to care for Point-of-Care customers in and out of the hospital.

Philips continues to build suites of intelligent and automated enhancements integrated into Radiology workflows across its portfolio to benefit customers and patients alike. By facilitating the development and integration of AI-enabled applications, Philips aims to enhance its ability to deliver on the Quadruple Aim of better patient outcomes, improved patient and staff experiences and lower cost of care. The integration of AI applications within ultrasound technology can also help lead to improved access to care.

While ultrasound is a cost-efficient diagnostic imaging modality, it currently requires a significant level of operator experience and visual interpretation to use it effectively. In particular, the subjectivity and variability associated with visual interpretation pose a challenge for longitudinal assessments to gauge patient improvement or deterioration. To reduce the variability, improve the efficiency and increase the accuracy of image analysis, DiA Imaging has developed FDA cleared and CE-marked AI-enabled 2D ultrasound applications.

“This partnership with DiA Imaging Analysis reinforces Philips’ commitment to integrating AI partners into the Radiology workflow ecosystem, from the modality, to interpretation, all the way through to results communication,” said Kees Wesdorp, Chief Business Leader, Precision Diagnosis at Philips. “Through our strategic partnership with DiA Imaging Analysis, we can deliver unprecedented diagnostic confidence and operational efficiency to point-of-care ultrasound imaging, as well as widen access to high quality and timely care both inside and outside of hospitals.”

“With superb image quality and ability to operate with smartphones and tablets, Philips Ultrasound devices are widely accepted as the industry’s most advanced solution for point-of-care imaging. As such, it is the ideal platform for deploying AI-enabled solutions that will benefit patients by helping clinicians to make better-informed decisions,” said Hila Goldman Aslan, CEO and Co-Founder, of DiA Imaging Analysis Ltd.

DiA’s AI technology automates the process of manually capturing and visually analyzing ultrasound images. The company’s LVivo Toolbox includes a range of FDA cleared and CE marked automated AI-enabled apps focused on cardiac and abdominal ultrasound analysis to help support clinicians with varying levels of ultrasound experience.

Philips will spotlight its AI-enabled solutions across its imaging portfolio at the upcoming  European Congress of Radiology 2021 virtual event (March 3-7, 2021). For more information on Philips’ new portfolio of diagnostic and interventional solutions, including the new Philips Abdominal Aortic Aneurysm (AAA) Model which seamlessly integrates 3D Ultrasound with innovative software in a single solution, visit the Philips ECR site, and follow @PhilipsLiveFrom for updates throughout the event.

* As part of the partnership, Philips owns a minority interest in DiA Imaging Analysis.

For further information, please contact:

Kathy O’Reilly
Philips Global Press Office
Tel.: +1 978-221-8919
E-mail : kathy.oreilly@philips.com
Twitter: @kathyoreilly

Edith Schlanger
DiA Imaging Analysis
E-mail: edith@dia-analysis.com

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2020 sales of EUR 19.5 billion and employs approximately 82,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

 

About DiA Imaging Analysis Ltd.

DiA Imaging Analysis is a leading provider of AI-powered ultrasound analysis solutions that make the use and analysis of ultrasound images smarter, faster and accessible to all. The company’s FDA cleared and CE marked LVivo product line for cardiac and abdominal auto analysis allow clinicians with various levels of ultrasound experience to use and analyze ultrasound images on their ultrasound devices or healthcare IT systems with increased speed, efficiency and accuracy. DiA currently serves thousands of end users worldwide. For additional information, please visit www.dia-analysis.com

Attachments

Philips spotlights new integrated informatics and system solutions to drive workflow optimization and advance precision diagnosis at ECR 2021

March 2, 2021 

  • Expanded Philips Radiology Workflow Suite features new, AI-enabled solutions to streamline workflows across the entire imaging enterprise
  • Solutions integrate and automate workflow to help improve efficiency and clinical confidence to enable earlier and more definitive diagnosis
  • Philips’ portfolio of award-winning diagnostic systems and interventional solutions will be featured in a unique virtual ECR experience

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced its participation in the European Congress of Radiology (ECR) virtual event, March 3-7, 2021, where the company will feature new and enhanced diagnostic and interventional solutions that further expand its Radiology Workflow Suite, connecting data, technology and people across the imaging enterprise. In furthering its commitment to workflow optimization, Philips will present how connected, smart systems and simpler, more efficient workflows can help reduce variability and staff workload, increase productivity, and enhance the patient & provider experience.

In 2020, the amount of health data surpassed 2,000 extabytes [1], while the number of radiology exams with advanced modalities increased by 43% [2]. Despite advances in technology, radiology services continue to struggle to connect workflows to support patients and staff with the information and tools they need to provide the right care in the right sequence at the right time. Moreover, repeat, low-value, and unnecessary imaging exams cost as much as EUR 10 billion annually [3]. The situation has been further exacerbated by COVID-19, where radiology departments are challenged to combine exams and procedures for patients with cancer, heart disease, and other conditions, while continuing to support critical care for COVID patients.

Integrated, smart solutions for more confident decision-making
The effective capture, analysis and reporting of data is at the core of modern diagnosis. At ECR 2021, Philips will showcase integrated, end-to-end solutions designed to provide more informed and confident decision-making. With the challenges of COVID-19 adding to existing stress on imaging departments, Philips has furthered its commitment to a “systems view” of imaging, focused on the specific challenges that patients, staff, clinicians, and administrators experience at each phase of the imaging pathway. Innovative solutions address system-wide challenges through the integration, digitization, and virtualization of the radiology workflow.

“By combining the power of imaging with insights from integrated diagnostics and AI, we can deliver diagnostic studies right the first time and optimize workflows to support staff efficiency, operational excellence, and continuous performance improvement,” said Kees Wesdorp, Chief Business Leader, Precision Diagnosis, at Philips. “At ECR, we will further demonstrate how Philips’ radiology workflow solutions are integrating complex data and analytics capabilities to inform timely, contextual diagnostic decision-making to guide caregivers and patients through more precise, personalized care pathways for better patient outcomes. This is the real promise of precision diagnosis.”

New solutions supporting Philips Radiology Workflow Suite at ECR
Philips will debut new technologies supporting its vendor-agnostic Radiology Workflow Suite at ECR, alongside its robust portfolio of clinically optimized diagnostic and interventional solutions. Philips Radiology Workflow Suite helps drive clinical and operational efficiency across all phases of the diagnostic enterprise, from scheduling and preparation, to image acquisition and data interpretation, to reporting and care pathway selection and treatment. New and enhanced solutions supporting Philips Radiology Workflow Suite include:

  • Philips Collaboration Live for Tele-Ultrasound. Provides real-time remote access to streamline communication and real-time support. Expanded access allows for better collaboration to treat patients. Clinicians have the flexibility to use text, voice call, screen sharing, webcam feed and remote system control to deliver remote consults to the exam room for real-time consults on complex exams.
  • Philips Engage. Remote patient management digital solution provides a clear overview of the patient’s available health information. The portal offers insight into files and treatment progress, allowing healthcare providers to do screenings, measure results, make video calls, chat, and prepare interventions for the patient.
  • Philips Clinical Pathways for Lung and Prostate Cancer. As cancer treatment becomes more complex and expensive, integrated oncology, pathology and genomics solutions enable end-to-end oncology care. From molecular diagnostics to therapy options, Philips Clinical Pathways streamline oncology care across the patient journey.
  • Philips Radiology Operations Command Center. The industry’s first vendor-agnostic, multi-modality radiology virtual imaging command center to enable real-time, remote collaboration between technologists, radiologists and imaging operations teams across multiple sites via private, secure telepresence capabilities.

Philips takes a holistic approach to integrating AI across its Precision Diagnosis portfolio, both for image processing and interpretation and for image acquisition, where automated and AI-enabled ‘smart workflows’ can increase efficiency and boost clinical confidence for system operators. Philips’ commitment to integrating data, AI, and analytics solutions supports its growing ecosystem approach, benefitting customers and the patients they serve. At ECR Philips is also showcasing innovations to enhance productivity and clinical confidence in diagnostic X-ray.

Spotlight on innovative Diagnostic Systems and Interventional Solutions
In addition to the new technology introductions supporting the Radiology Workflow Suite during ECR, Philips will showcase the latest innovations across its comprehensive portfolio of diagnostic and interventional solution. These include:

  • Precise Suite with AI for the Philips Incisive CT. The solution combines advances in AI reconstruction techniques and camera-based workflow, for motion-free cardiac scans and interventional procedures. Philips Incisive enhances the CT experience for patients and staff while controlling costs across the organization to help meet the most pressing financial, clinical and operational goals.
  • Philips enterprise imaging solutions, including its Vendor-Neutral Image Viewer (Vue Motion), KLAS Research’s 2021 Best in KLAS Universal Viewer (Imaging) award winner, and Philips Advanced Visualization Workspace, IntelliSpace Portal 12, honored with a EuroMinnie Award in the Best New Radiology Software category.
  • Philips’ next-generation Azurion image-guided therapy platform marks  an important step forward in optimizing clinical and operational lab performance and expanding the role of image-guided interventions in the treatment of patients.  An industry first, the advanced image-guided therapy platform now integrates control of imaging, IVUS (Intravascular Ultrasound), physiology, hemodynamic and informatics applications, as well as intuitive control of the gantry, at the tableside, allowing clinicians to control all compatible applications from a single touchscreen and helping to decide, guide, treat and confirm the right care in real time.

Philips virtual experience and symposia sessions at ECR 2021
From March 3 to March 7, visitors to the Philips 3D virtual ECR environment can access the latest breakthrough innovations from Philips, including interactive product demos streamed live from the Philips Customer Experience Center in Best, the Netherlands. Unique this year, Philips is also teaming with European Society of Radiology to create content airing on the ECR main TV channel to discuss ‘Creating Workflows of support across the imaging enterprise,’ featuring first-hand accounts of the impact disconnected systems have on the day-to-day lives of patients and clinicians. Philips will also host two symposia sessions during ECR addressing critical areas of challenge and opportunity for radiology leaders:

How imaging meets the challenges of COVID-19, today and into the future
► Thursday, March 4 | 8:00 – 9:00 CET

Smart Workflows: Improving imaging productivity and clinical confidence with AI
► Friday, March 5 | 9:15 – 10:15 CET

For more information on Philips’ new portfolio of diagnostic and interventional solutions and AI-enabled applications to enhance radiology workflows at ECR 2021, visit www.philips.com/ecr and follow @PhilipsLiveFrom for updates throughout the event.

Philips’ triple duty of care and sustainability commitments
The COVID-19 pandemic continues to highlight how interconnected the world’s social, economic and environmental challenges are. Philips remains fully focused on delivering against its triple duty of care: meeting critical customer needs, safeguarding the health and safety of its employees, and ensuring business continuity. The company is deeply committed to doing business responsibly and sustainably, recently meeting its ‘Healthy people, sustainable planet targets,’ as one of the first health technology companies in the world to become fully carbon neutral in its operations. With the COVID-19 pandemic and climate change exposing the risks in terms of people’s health and access to quality healthcare, Philips is committed to building inclusive and resilient healthcare systems, while reducing its dependency on natural resources.

[1]  https://med.stanford.edu/content/dam/sm/sm-news/documents/StanfordMedicineHealthTrendsWhitePaper2017.pdf
[2] https://www.statnews.com/2018/10/19/consolidation-hurting-hospital-supply-chain-costs/
[3] https://www.reactiondata.com/report/unnecessary-imaging/

For further information, please contact:

Kathy O’Reilly
Philips Global Press Office
Tel. : +1 978-221-8919
E-mail : kathy.oreilly@philips.com
Twitter: @kathyoreilly

Mark Groves
Philips Global Press Office
Tel.: +31 631 639 916
E-mail: mark.groves@philips.com

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2020 sales of EUR 19.5 billion and employs approximately 82,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

[OLK1]Link to Press Backgrounder which will contain the hero solutions from the radiology solutions list and IGT.

Attachments

Teledyne e2v and Yumain announce collaboration to create AI-based imaging solutions for machine vision

GRENOBLE, France, March 02, 2021 (GLOBE NEWSWIRE) — Teledyne e2v, a Teledyne Technologies [NYSE: TDY] company and global innovator of imaging solutions, announces a new technology and industrial collaboration with Yumain (Dijon, France), a leading AI vision solution provider serving a broad range of industrial applications. Together, the companies will develop cutting-edge bio-inspired vision solutions that can enable innovation in industrial applications.

The recent emergence of AI for industry has rapidly demonstrated its benefits over traditional rule-based methods which have been proven to be unsuitable for applications with high variability e.g. the inspection of complex surfaces with irregularities (brushed aluminum, wood etc.). Yet to be harnessed to its full potential and for AI to be adopted globally, it must be easily setup and trained, optimized by users within minutes (without any AI expertise), provide reliable results, be flexible in application, secure, and low power. By joining forces, Teledyne e2v and Yumain plan to develop significant breakthrough innovations to address these challenges, make AI technology more accessible, and advance it to the next level.

Vincent Hector, Vice President of Market Development at Teledyne e2v, says, “We’re very excited to be collaborating with Yumain on this innovative project. Our image sensor capability coupled with their tailored AI expertise will allow us to develop AI-based vision solutions which will be easily accessible for industrial customers and bring real benefits to their applications.”

Marc Benoit, Managing Director of Yumain, commented, “Edge AI, as we know it today, consists of an optimization of machine learning models and computation inherited from the cloud. We have 10 years of experience in this field, which has shown us that alternative implementations of AI could be more suitable and scalable for the constraints of factory and production lines. Teledyne e2v’s image sensor design and production expertise are paramount to bringing these novel ideas to reality. This initiative is a key milestone for us and one that emphasizes our potential to investors.”

For media enquiries, please contact:
Jessica.Broom@teledyne.com | + 44 (0)1245 453607

Teledyne e2v is part of the Teledyne Imaging Group. Their innovations lead developments in healthcare, life sciences, space, transportation, defence and security and industrial markets. Teledyne e2v’s unique approach involves listening to the market and application challenges of customers and partnering with them to provide innovative standard, semi-custom or fully-custom imaging solutions, bringing increased value to their systems. For more information, visit imaging.teledyne-e2v.com

Yumain, is a private company based in Dijon, France. Founded in 2011 by an experienced management and academic team, they design and manufacture intelligent vision systems and cameras for Industry 4.0. By leveraging a background in Artificial Intelligence and software and hardware design they serve international clients by focusing on predictive maintenance, quality control, industrial robots and risk prevention. Their approach is based on a unique analysis and real-time decision making process which is made directly from an image. This is acknowledged as a key achievement by their customers and has also received multiple awards from their peers. For more information, visit www.yumain.fr/en/home

Teledyne Imaging is a group of leading-edge companies aligned under the Teledyne umbrella. Teledyne Imaging forms an unrivalled collective of expertise across the spectrum with decades of experience. Individually, each company offers best-in-class solutions. Together, they combine and leverage each other’s strengths to provide the deepest, widest imaging and related technology portfolio in the world. From aerospace through industrial inspection, scientific research, spectroscopy, radiography and radiotherapy, geospatial surveying, and advanced MEMS and semiconductor solutions, Teledyne Imaging offers world-wide customer support and the technical expertise to handle the toughest tasks. Their tools, technologies, and vision solutions are built to deliver to their customers a unique and competitive advantage. For more information, visit www.teledyneimaging.com

Shez Partovi to succeed Jeroen Tas as Philips’ Chief Innovation & Strategy Officer

March 2, 2021

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that Shez Partovi will join Philips’ Executive Committee, effective from March 22, 2021, in order to succeed Jeroen Tas as Chief Innovation & Strategy Officer, effective from July 1, 2021. Mr. Partovi will report directly to CEO Frans van Houten and work closely with Mr. Tas to ensure a seamless transition.

Mr. Partovi (Canadian, 1967) joins Philips from Amazon Web Services (AWS), where he served as Worldwide Head of Business Development for Healthcare, Life Sciences and Medical Devices. In that role, he was responsible for the global AWS go-to-market strategy, charting the path for customer cloud transformation, and the adoption of artificial intelligence and machine learning. Prior to joining AWS in 2018, Mr. Partovi spent 20 years at Dignity Health, the fifth largest health system in the U.S. He started his career in 1998 as a neuroradiologist at the Barrow Neurological Institute and was in clinical practice until 2013. In addition to his medical training at McGill University in Montreal, he has post-graduate qualifications in computer science. Mr. Partovi has a passion for learning and teaching. He helped launch the Biomedical Informatics Department at Arizona State University and taught there as a clinical professor for three years.

Mr. Tas, who joined Philips in 2011 as Chief Information Officer and became Chief Innovation & Strategy Officer in 2017, has made a personal decision to assume a part-time position in Philips focused on continuation of the company’s strategic business development until the end of 2022. This will allow him to spend more time on coaching digital business ventures.

Philips also today announced that Rob Cascella, currently Strategic Business Development Leader and formerly in charge of Philips’ Diagnosis & Treatment segment, will step down from the Executive Committee as planned, effective from April 1, 2021, to begin the process of retiring from the company. Mr. Cascella has agreed to act as a special advisor to Philips’ strategic business development projects on a part-time basis until the end of 2021.

“On behalf of Philips’ Executive Committee, I am very pleased to welcome Shez Partovi as our new Chief Innovation & Strategy Officer,” said Frans van Houten, CEO of Royal Philips. “Shez brings deep healthcare and informatics experience to Philips, which will be highly relevant as we accelerate the transition to becoming a solutions leader, leveraging deep clinical insights and big data analytics. I want to thank Jeroen and Rob for their very valuable contributions to the transformation of our company. Jeroen played a very important role in inspiring and executing our strategy for digital health and healthcare informatics, while Rob has contributed a wealth of experience and successfully shaped our Diagnosis & Treatment segment.”

Additional information on Philips’ Executive Committee can be found here.

For further information, please contact:

Ben Zwirs
Philips Global Press Office
Tel.: +31 6 1521 3446
E-mail: ben.zwirs@philips.com

Derya Guzel
Philips Investor Relations
Tel.: +31 20 59 77055
E-mail: derya.guzel@philips.com

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2020 sales of EUR 19.5 billion and employs approximately 82,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachments

WillScot Mobile Mini Announces Pricing of Upsized Secondary Offering

PHOENIX, March 01, 2021 (GLOBE NEWSWIRE) — WillScot Mobile Mini Holdings Corp. (“WillScot Mobile Mini” or the “Company”) (Nasdaq: WSC), a North American leader in modular space and portable storage solutions, today announced the pricing of an upsized underwritten, secondary offering (the “Offering”) of 12,750,000 shares (the “Shares”) of its common stock, par value $0.0001 per share (the “Common Stock”). The Shares have been offered by the Company’s principal shareholder, Sapphire Holding S.à r.l., an entity controlled by TDR Capital (the “Selling Stockholder”), at a price to the public of $27.20 per share. The Company had previously announced the offering of 10,750,000 shares of Common Stock by the Selling Stockholder. The Selling Stockholder granted the underwriter a 30-day option to purchase up to an additional 1,912,500 shares. The Company has not offered any shares in the Offering and will not receive any of the proceeds from the Offering. The closing of the Offering is expected to occur on March 4, 2021.

Morgan Stanley has acted as sole underwriter for the Offering.

The Offering is being made pursuant to an effective shelf registration statement, as amended, including a base prospectus, that has been filed with the Securities and Exchange Commission (the “SEC”) and became automatically effective on March 1, 2021 and is available on the SEC’s website. A preliminary prospectus supplement and the accompanying base prospectus related to the Offering were filed with the SEC on March 1, 2021 and are available on the SEC’s website. Copies of these documents may be obtained from: Morgan Stanley & Co. LLC, 180 Varick Street, 2nd Floor, New York, NY 10014, Attention: Prospectus Department.

In addition, the Company has entered into a share repurchase agreement with the Selling Stockholder pursuant to which it will repurchase 2,750,000 shares of Common Stock directly from the Selling Stockholder (the “Share Repurchase”). The price per share to be paid by the Company will be equal to the price per Share paid by the underwriters for the Shares in the Offering. The Company expects to fund the Share Repurchase from borrowings under its ABL Credit Facility. The Share Repurchase is expected to be consummated concurrently with the closing of the Offering. Although the Share Repurchase is conditioned upon the closing of the Offering, the closing of the Offering is not conditioned upon the closing of the Share Repurchase.

This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities of the Company, nor shall there be any sale of securities of the Company in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended. The words “estimates,” “expects,” “anticipates,” “believes,” “forecasts,” “plans,” “intends,” “may,” “will,” “should,” “shall,” “outlook” and variations of these words and similar expressions identify forward-looking statements, which are generally not historical in nature. Certain of these forward-looking statements include statements relating to the timing and conduct of the Offering, the size and terms of the Offering and the closing of the Offering. Forward-looking statements are subject to a number of risks, uncertainties, assumptions and other important factors, many of which are outside our control, which could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. These risks include, without limitation, risks and uncertainties related to market conditions, that the size of the Offering could change or the Offering could be terminated, and the satisfaction of customary closing conditions related to the Offering. Any forward-looking statement speaks only at the date which it is made, and WillScot Mobile Mini disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

About WillScot Mobile Mini Holdings Corp.

WillScot Mobile Mini Holdings trades on the Nasdaq stock exchange under the ticker symbol “WSC”. Based in Phoenix, Arizona, WillScot Mobile Mini Holdings is a North American leader in turnkey modular space and portable storage solutions. It was formed in 2020 upon the merger of leaders in the modular space and portable storage markets. Together the WillScot and Mobile Mini brands operate approximately 275 locations across the United States, Canada, Mexico, and the United Kingdom with a combined fleet of over 350,000 portable offices and storage containers. The company leases turnkey office space and storage solutions for temporary applications across a diverse customer base in the commercial and industrial, construction, retail, education, health care, government, transportation, security and energy sectors. WillScot Mobile Mini creates value by enabling customers to add space efficiently and cost-effectively – when the solution is perfect, productivity is all the customer sees.

Contact Information

Investor Inquiries:

Nick Girardi
nick.girardi@willscotmobilemini.com

Media Inquiries:

Scott Junk
scott.junk@willscotmobilemini.com

WillScot Mobile Mini Announces Launch of Secondary Offering and Concurrent Stock Repurchase

PHOENIX, March 01, 2021 (GLOBE NEWSWIRE) — WillScot Mobile Mini Holdings Corp. (“WillScot Mobile Mini” or the “Company”) (Nasdaq: WSC), a North American leader in modular space and portable storage solutions, today announced the launch of an underwritten, secondary offering (the “Offering”) of 10,750,000 shares (the “Shares”) of its common stock, par value $0.0001 per share (the “Common Stock”). The Shares are being offered by the Company’s principal shareholder, Sapphire Holding S.à r.l., an entity controlled by TDR Capital (the “Selling Stockholder”). The Selling Stockholder expects to grant the underwriter a 30-day option to purchase up to an additional 1,612,500 shares. The Company is not offering any shares in the Offering and will not receive any of the proceeds from the Offering.

Morgan Stanley is acting as sole underwriter for the Offering.

The Offering is being made pursuant to an effective shelf registration statement, as amended, including a base prospectus, that has been filed with the Securities and Exchange Commission (the “SEC”) and became automatically effective on March 1, 2021 and is available on the SEC’s website. A preliminary prospectus supplement and the accompanying base prospectus related to the Offering have been filed with the SEC on March 1, 2021 and are available on the SEC’s website. Copies of these documents may be obtained from: Morgan Stanley & Co. LLC, 180 Varick Street, 2nd Floor, New York, NY 10014, Attention: Prospectus Department.

In addition, the Company announced that it has entered into a share repurchase agreement with the Selling Stockholder pursuant to which it intends to purchase 2,750,000 shares of Common Stock directly from the Selling Stockholder (the “Share Repurchase”). The price per share to be paid by the Company will be equal to the price per Share paid by the underwriters for the Shares in the Offering. The Company expects to fund the Share Repurchase from borrowings under its ABL Credit Facility. The Share Repurchase is expected to be consummated concurrently with the closing of the Offering. Although the Share Repurchase will be conditioned upon, among other things, the closing of the Offering, the closing of the Offering will not be conditioned upon the closing of the Share Repurchase.

This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities of the Company, nor shall there be any sale of securities of the Company in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended. The words “estimates,” “expects,” “anticipates,” “believes,” “forecasts,” “plans,” “intends,” “may,” “will,” “should,” “shall,” “outlook” and variations of these words and similar expressions identify forward-looking statements, which are generally not historical in nature. Certain of these forward-looking statements include statements relating to the timing and conduct of the Offering, the size and terms of the Offering and the closing of the Offering. Forward-looking statements are subject to a number of risks, uncertainties, assumptions and other important factors, many of which are outside our control, which could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. These risks include, without limitation, risks and uncertainties related to market conditions, that the size of the Offering could change or the Offering could be terminated, and the satisfaction of customary closing conditions related to the Offering. Any forward-looking statement speaks only at the date which it is made, and WillScot Mobile Mini disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

About WillScot Mobile Mini Holdings Corp.

WillScot Mobile Mini Holdings trades on the Nasdaq stock exchange under the ticker symbol “WSC”. Based in Phoenix, Arizona, WillScot Mobile Mini Holdings is a North American leader in turnkey modular space and portable storage solutions. It was formed in 2020 upon the merger of leaders in the modular space and portable storage markets. Together the WillScot and Mobile Mini brands operate approximately 275 locations across the United States, Canada, Mexico, and the United Kingdom with a combined fleet of over 350,000 portable offices and storage containers. The company leases turnkey office space and storage solutions for temporary applications across a diverse customer base in the commercial and industrial, construction, retail, education, health care, government, transportation, security and energy sectors. WillScot Mobile Mini creates value by enabling customers to add space efficiently and cost-effectively – when the solution is perfect, productivity is all the customer sees.

Contact Information

Investor Inquiries:

Nick Girardi

nick.girardi@willscotmobilemini.com

Media Inquiries:

Scott Junk

scott.junk@willscotmobilemini.com